<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164121</url>
  </required_header>
  <id_info>
    <org_study_id>FLZPD1002</org_study_id>
    <nct_id>NCT04164121</nct_id>
  </id_info>
  <brief_title>A Clinical Study Trial of Phenlarmide in China</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose, Incremental Tolerance and Pharmacokinetics Study of Phenlarmide Tablets in Chinese Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yiling Pharmaceutical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yiling Pharmaceutical Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the tolerance and safety of FLA tablets in healthy volunteers.

        2. To evaluate the pharmacokinetics of FLA tablets in healthy volunteers.

        3. Provide basis for dosage setting for follow-up clinical research.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">October 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance evaluation index</measure>
    <time_frame>From 0 to 20 days after dosing</time_frame>
    <description>maximum tolerated dose (MTD), dose limited toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The amount of time that a drug is present at the maximum concentration in serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time (MRT) parameter</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kel</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-∞)</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last</measure>
    <time_frame>From 0 to 168 hours after the first dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax, ss</measure>
    <time_frame>From 0 to 72 hours after the last dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, ss</measure>
    <time_frame>From 0 to 72 hours after the last dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin, ss</measure>
    <time_frame>From 0 to 72 hours after the last dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cavg, ss</measure>
    <time_frame>From 0 to 72 hours after the last dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2, ss</measure>
    <time_frame>From 0 to 72 hours after the last dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24, ss</measure>
    <time_frame>From 0 to 72 hours after the last dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72, ss</measure>
    <time_frame>From 0 to 72 hours after the last dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞, ss</measure>
    <time_frame>From 0 to 72 hours after the last dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last, ss</measure>
    <time_frame>From 0 to 72 hours after the last dose</time_frame>
    <description>The PK parameters of the plasma sample</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>FLZ-150mg experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLZ-150mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLZ-600mg experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLZ-600mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLZ-900mg experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLZ-900mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenlarmide Tablets</intervention_name>
    <description>Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.</description>
    <arm_group_label>FLZ-150mg experimental</arm_group_label>
    <arm_group_label>FLZ-600mg experimental</arm_group_label>
    <arm_group_label>FLZ-900mg experimental</arm_group_label>
    <other_name>FLZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.</description>
    <arm_group_label>FLZ-150mg placebo</arm_group_label>
    <arm_group_label>FLZ-600mg placebo</arm_group_label>
    <arm_group_label>FLZ-900mg placebo</arm_group_label>
    <other_name>FLZ-Placebos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1)18-65 years old (including upper and lower limits);

          -  2)Men and women are not limited;

          -  3)Men weigh more than 50 kg, women weigh more than 45 kg, BMI 19-28 kg/m2 (including
             upper and lower limits);

          -  4)Understand and sign the informed consent, understand the research process and
             requirements, and volunteer to participate in this study.

        Exclusion Criteria:

          -  1)There is a history of heart, liver, kidney, respiratory, digestive tract, nervous
             system, endocrine, immune or hematological diseases judged by researchers as having
             clinical significance;

          -  2)There are abnormalities in vital signs, general physical examination, laboratory
             examination and ECG examination, which are judged to be of clinical significance by
             researchers;

          -  3)Any drug was taken within two weeks before the study was administered, and the
             researchers believe that this condition may affect the evaluation results of the
             study;

          -  4)There is a significant history of drug allergy or hypersensitivity in food that
             researchers have identified as clinically significant;

          -  5)The positive results of serological tests (HBsAg, anti-HCV, anti-HIV or TP-Ab) were
             found at the time of screening;

          -  6)One year before the study was administered, some researchers believed that alcohol
             or drug abuse history might affect the results of this study, or that alcohol breath
             test or urine drug screening test were positive during screening;

          -  7)Those who had smoking history within three months before the first administration or
             who had positive urinary cotinine test in screening stage;

          -  8)Those who participated in any clinical trial within 3 months before administration;

          -  9)Those who donated blood more than 400 mL or 2 units within 3 months before
             administration;

          -  10)Do not agree to avoid the use of tobacco, alcohol or caffeine-containing beverages
             within 24 hours before and during the trial, or to avoid vigorous exercise, or to
             avoid other factors affecting drug absorption, distribution, metabolism and excretion;

          -  11)Pregnant or lactating women, or those with positive serum HCG test before
             administration, or those who are unable or unwilling to adopt contraceptive measures
             approved by the researchers during the study period and within three months after the
             end of the study, as directed by the researchers;

          -  12)Researchers do not consider it suitable for participants in this clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>mingming Li</last_name>
    <phone>15032188589</phone>
    <email>limingming@yiling.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking union medical college hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yahong Lv</last_name>
      <phone>17603260441</phone>
      <email>lvyahong@yiling.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerance</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetic characteristics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

